Dr. Paty on High-Risk Period for Rectal Tumor Regrowth

Video

In Partnership With:

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses the high-risk period for rectal tumor regrowth in patients.

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses the high-risk period for rectal tumor regrowth in patients.

The high-risk period for regrowth of the tumor is the first 18 months following treatment, Paty explains. In this window, most practitioners who are conducting the "watch-and-wait" approach are doing so with patients in 3- to 4-month intervals. This would include a digital exam with a flexible fiberoptic sigmoidoscopy, careful examination of the rectum and tumor bed, and any scarring. The clinical examination is supplemented by cross-sectional imaging. High-resolution MRI is the optimal technique to use, especially when assessing the lymph nodes.

After the 2-year period, the risk of local cancer regrowth drops significantly, he adds, and patients are then examined at 6-month intervals. Currently, most researchers believe that patients should continue to be assessed annually for the remainder of their lives.

Related Videos
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center